Warren Center For Neuroscience Drug Discovery
-
Drug discovery efforts continue in latest chemical chronicle from the Warren Center for Neuroscience Drug Discovery
Led by Craig W. Lindsley, Vanderbilt drug discovery experts set out to develop a backup drug candidate to improve memory loss in people with Alzheimer’s disease. Read MoreOct 31, 2024
-
Celebrating Vanderbilt’s inspiring achievements during Sesquicentennial year
See some of the bold and collaborative actions Vanderbilt University accomplished this year an innovator and leader in solving the world’s most pressing challenges. Read MoreMay 23, 2024
-
Discovery Vanderbilt sends research soaring
On October 17, 2022, Vanderbilt University launched “Discovery Vanderbilt” to embolden faculty, students and staff to pursue innovative ideas through disciplined, rigorous inquiry. Led by Provost Cybele Raver, the university committed $80 million in the effort—and invested $50 million in the first year alone. Read MoreApr 15, 2024
-
Watch now: Lab-to-Table Conversation: Beyond Addiction: Therapeutic Developments and Societal Impact
Join the next Lab-to-Table conversation, “Beyond Addiction: Therapeutic Developments and Societal Impact” on Jan. 24 at 11:30 a.m. CT. Read MoreJan 11, 2024
-
Innovation Ignition Fund launches a pilot program to support early-stage therapeutic projects with translational viability
The School of Medicine Basic Sciences and the Office of the Vice Provost for Research and Innovation launch the Innovation Ignition Fund. This pilot program offers up to $500,000 in funding and drug development mentorship from Vanderbilt scientists with expertise in translational research. Read MoreJan 11, 2024
-
Potential schizophrenia treatment, discovered at Vanderbilt and being developed by Neumora Therapeutics, entering Phase 1 clinical trial
In just over two years, a Vanderbilt-Neumora collaboration has led to the Phase 1 clinical trial of a treatment for schizophrenia spectrum disorders, which affect 3.7 million adults in the United States. This is the third chemical compound discovered at the Warren Center for Neuroscience Drug Discovery to reach Phase 1 clinical trials. Read MoreDec 4, 2023
-
Warren Center for Neuroscience Drug Discovery added to Discovery Vanderbilt portfolio; philanthropic matching launched
Vanderbilt has announced the addition of the Warren Center for Neuroscience Drug Discovery into Discovery Vanderbilt as well as an initiative within the Dare to Grow campaign to inspire philanthropy with a one-to-one match for gifts of $100,000 or more. Read MoreDec 4, 2023
-
Vanderbilt scientists make headway in drug development to cure pulmonary arterial hypertension
Biomedical engineer David Merryman and Warren Center for Neuroscience Drug Discovery director Craig Lindsley have developed a new drug that treats PAH, a type of high blood pressure that affects arteries in the lungs and in the heart, without serious neurological side effects. Read MoreSep 13, 2023
-
Vanderbilt documentary ‘Speaking Through Me’ spotlights youth brain education for mental health and substance use disorder prevention
Kristen Gilliland, who lost her son to an accidental overdose, and the Warren Center for Neuroscience Drug Discovery premiered the documentary Speaking Through Me to educate teens on substance use and mental illness prevention. Read MoreAug 17, 2023
-
Made for This Moment: 150 years after its founding, Vanderbilt is poised to take its place among the greatest universities of this century
Stronger than at any other time in our history, we are positioned to do more than just meet the challenges of our times. We have what it takes to thrive and lead—to define and become the great university of this century. Read MoreJun 20, 2023
-
Lindsley named 2022 fellow of American Society for Pharmacology and Experimental Therapeutics
Craig W. Lindsley, University Distinguished Professor of Pharmacology, Biochemistry and Chemistry, who holds the William K. Warren, Jr. Chair in Medicine, was recently announced as a 2022 fellow of the American Society for Pharmacology and Experimental Therapeutics for his demonstrated excellence and contributions to pharmacology and to the ASPET organization. Read MoreNov 29, 2022
-
Vanderbilt, international collaborators discover treatment to slow neurodegenerative diseases
Warren Center for Neuroscience Drug Discovery lead researchers discover a therapy that may treat memory loss and slow the progression of Alzheimer’s disease. Read MoreNov 15, 2022
-
NIMH awards $3.4M to Womelsdorf to study how next generation of schizophrenia drugs affects brain networks, cognition
The National Institute of Mental Health has awarded a $3.4 million grant to professor Thilo Womelsdorf to study the underlying mechanisms of action for potential drugs to regulate cognitive function and brain network activity affected in schizophrenia without debilitating side effects. Read MoreApr 28, 2022
-
Prothena and Warren Center for Neuroscience Drug Discovery collaborate on new Alzheimer’s disease therapeutics
Prothena and the Warren Center for Neuroscience Drug Discovery have entered into a collaborative research agreement to develop new small molecule therapeutics for the treatment of Alzheimer’s disease in individuals with Down syndrome. Read MoreApr 22, 2022
-
Research Snapshot: Hunger signals, including those from cannabinoids, mapped in the brain
Body-made cannabinoids that fine tune hunger signals in the brain have been mapped, with implications for helping those with deadly feeding-related illnesses Read MoreMar 23, 2022
-
Colleen Niswender lands national award, several grants for Rett syndrome research
Colleen Niswender, associate professor of pharmacology and director of molecular pharmacology for the Warren Center for Neuroscience Drug Discovery, was awarded the ASPET Scientific Achievement Award in Drug Discovery and Development for her work in the development of novel treatments for neurological and psychiatric disorders. Read MoreMar 22, 2022
-
Vanderbilt inks collaboration with precision neuroscience company Neumora to continue development of investigational treatment for neuropsychiatric disorders
Vanderbilt University has signed an exclusive worldwide license and research collaboration agreement with Neumora Therapeutics, Inc., a clinical-stage biotechnology company pioneering precision medicines for brain diseases through the integration of data science and neuroscience. Read MoreFeb 22, 2022
-
Research Snapshot: Understanding the molecules and brain circuits recruited by stressful experience
Stressful events can rapidly modify how the brain responds to its environment and guides behaviors. These processes are relevant for neurotypical brain function and for the development of affective disorders and other psychiatric diseases, yet we have much to learn regarding the underlying molecular mechanisms. In this paper, researchers utilized pharmacologic, transgenic, and optogenetic tools to evaluate changes in brain function related to stress. Read MoreFeb 17, 2022
-
Ege Kavalali to lead pharmacology department in School of Medicine Basic Sciences
Ege T. Kavalali, William Stokes Professor of Experimental Therapeutics, has been named chair of the Department of Pharmacology in the Vanderbilt University School of Medicine Basic Sciences. Read MoreFeb 4, 2022
-
Vanderbilt-discovered drug candidate for Parkinson’s disease enters clinical trials
Appello Pharmaceuticals Inc. begins trial of a drug candidate that improves relief from symptoms of Parkinson’s disease without debilitating side effects. Read MoreOct 6, 2021